Skip to main content

Optogenetic Protein Therapy for Multiple Sclerosis

Objective

Optogenerapy proposes a new interferon-ß (IFN-ß) drug delivery system to revolutionize Multiple Sclerosis treatment.

The aim is to develop and validate a new bio-electronic cell based implant device to be implanted subcutaneously providing controlled drug release during at least 6 months. The cell confinement within a chamber sealed by a porous membrane allows the device to be easily implanted or removed. At the same time, this membrane acts to prevent immune rejection and offers long-term safety in drug release while overcoming the adverse effects of current cellular therapies. Wireless powered optogenetics – light controlling the cellular response of genetically engineered cells – is used to control the production of IFN-ß.

Replacing standard intravenous IFN-ß delivery by subcutaneous delivery prevents short and long term side effects and efficiency-losses related to drug peaks and discontinuation, while saving non-adherence costs.

It is a low-cost system enabling large scale manufacturing and reduction of time to market up to 30% compared to other cell therapies, combining:
- Polymeric biomaterials with strong optical, biocompatibility and barrier requirements, to build the cell chamber and to encapsulate the optoelectronics.
- Optoelectronics miniaturization, autonomy and optical performance.
- Optimal cellular engineering design, enhanced by computer modelling, for stability and performance of the synthetic optogenetic gene pathway over long-term implantation.
- Micro moulding enabling optoelectronics and membrane embedding for safety and minimal invasiveness.

The innovation potential is so huge that a proof-of-concept was listed by Scientist Magazine as one of the 2014’s big advances in science.

In our top-class consortium, industrial pull meets technological push, ensuring that the preclinically validated prototype obtained at the end responds to market demands.

BOSTON SCIENTIFIC, worldwide leader in neuromodulation active implants, has clear exploitation plans and high market penetration potential. 4 research intensive SMEs: TWO, GENEXPLAIN, NEOS and ULTRASION bring specific competences while increasing their own competitiveness.

Field of science

  • /social sciences/economics and business/business and management/commerce
  • /engineering and technology/electrical engineering, electronic engineering, information engineering/information engineering/telecommunications/wireless
  • /engineering and technology/industrial biotechnology/biomaterials
  • /medical and health sciences/basic medicine/neurology/multiple sclerosis
  • /natural sciences/physical sciences/electromagnetism and electronics/optoelectronics
  • /medical and health sciences/medical biotechnology/medical bioproducts/implants

Call for proposal

H2020-NMBP-2016-two-stage
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

FUNDACIO EURECAT
Address
Avenida Universitat Autonoma 23
08290 Cerdanyola Del Valles (Barcelona)
Spain
Activity type
Research Organisations
EU contribution
€ 1 256 557,50

Participants (10)

EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH
Switzerland
EU contribution
€ 0
Address
Raemistrasse 101
8092 Zuerich
Activity type
Higher or Secondary Education Establishments
BOSTON SCIENTIFIC LIMITED
Ireland
EU contribution
€ 805 880
Address
Ballybrit Business Park
H91 Galway
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
TWOPTICS SYSTEMS DESIGN SL
Spain
EU contribution
€ 246 410
Address
Calle Jordi Girona 1-3 Parc Upc Edificio K2m Off 316 Campus Nord
08034 Barcelona
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
POLITECHNIKA LODZKA
Poland
EU contribution
€ 255 000
Address
Ulica Zeromskiego 116
90 924 Lodz
Activity type
Higher or Secondary Education Establishments
GENEXPLAIN GMBH
Germany
EU contribution
€ 386 100
Address
Am Exer 19 B
38302 Wolfenbuttel
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
EU contribution
€ 951 345
Address
Rue De Tolbiac 101
75654 Paris
Activity type
Research Organisations
NEOS SURGERY SL
Spain
EU contribution
€ 303 375
Address
Paseo Mikeletegi - Parque Tecnologico Miramon 2
20009 Donostia San Sebastian
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ULTRASION S.L.
Spain
EU contribution
€ 172 500
Address
Av. Universitat Autonoma 23
08290 Cerdanyola Del Valles
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ERASMUS UNIVERSITEIT ROTTERDAM
Netherlands
EU contribution
€ 322 590
Address
Burgemeester Oudlaan 50
3062 PA Rotterdam
Activity type
Higher or Secondary Education Establishments
ASOCIACION ESPANOLA DE NORMALIZACION
Spain
EU contribution
€ 77 500
Address
Calle Genova 6
28004 Madrid
Activity type
Other